|
|
Consulting Reports
From Office of Health Economics Contact information at EDIRC. Bibliographic data for series maintained by Publications Manager (). Access Statistics for this working paper series.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.
- 001978: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
- A. Towse and M. Garau
- 001976: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
- Amanda Cole, O'Neill, P., Christopher Sampson and Paula Lorgelly
- 001944: Review of CRA's Report "Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe"
- J. Mestre-Ferrandiz, M. Berdud and A. Towse
- 001933: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
- F. Maignen, M. Berdud, G. Hampson and Paula Lorgelly
- 001932: Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
- B. Zamora, F. Maignen and Paula Lorgelly
- 001910: Data Governance Arrangements for Real-World Evidence: South Korea
- E.k Lee, J.a Park, Amanda Cole and J. Mestre-Ferrandiz
- 001818: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
- B. Zamora, F. Maignen, O'Neill, P., J. Mestre-Ferrandiz and M. Garau
- 001802: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
- G. Marsden and A. Towse
- 001784: Policy Options for Formulary Development in Middle-income Countries
- K. Hernandez-Villafuerte, M. Garau, A. Towse, L. Garrison and S. Grewal
- 001781: Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
- K. Hernandez-Villafuerte, M. Garau, T. Towse and L. Garrison
- 001748: Improving Efficiency and Resource Allocation in Future Cancer Care
- Amanda Cole, A. Lundqvist, Paula Lorgelly, H. Norrlid, S. Karlsberg Schaffer, F. Lewis, K. Hernandez-Villafuerte, P. Lindgren, M. Garau, K-O Welin, S. Bianchi, R. Althin, O'Neill, P., U. Persson and A. Towse
- 001743: Four Case Studies to Explore the Added Value of Oxford AHSN
- G. Marsden, A. Martin, B. Zamora, J. Exley, J. Sussex and A. Towse
- 001699: Shaping Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
- S. Karlsberg Schaffer, Patricia Cubi-Molla, N. Devlin and A. Towse
- 001688: Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
- O'Neill, P. and B. Zamora
- 001660: Data Governance Arrangements for Real-World Evidence
- Amanda Cole, L. Garrison, J. Mestre-Ferrandiz and A. Towse
- 001645: Estimation of Future Cases of Dementia from Those Born in 2015
- F. Lewis
- 001611: International Comparison of Medicines Usage: Quantitative Analysis from a Swedish Perspective
- O'Neill, P. and J. Sussex
- 001595: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
- A. Chapman and S. Karlsberg Schaffer
- 001576: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?
- Koonal Shah, A. Chapman, N. Devlin and P. Barnsley
- 001504: Obstructive Sleep Apnoea: Health Economics Report
- J.c Rejon-Parrilla, M. Garau and J. Sussex
- 000518: The Trajectory of Dementia in the UK - Making a Difference
- F. Lewis, S. Karlsberg Schaffer, J. Sussex, O'Neill, P. and L. Cockcroft
- 000271: The Many Faces of Innovation
- Consulting Ohe
- 000265: Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
- A. Gray, P. Fenn, M. Garau, C. Pritchard, E. Godber and A. Towse
- 000236: Medical Research: What's It Worth?
- Office of Health Economics Health Economics Research Group and Europe Rand
- 000234: Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience
- M. Garau, Koonal Shah, A. Towse, Q. Wang, M.f Drummond and A. R. Mason
- 000229: Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending
- J. Mestre-Ferrandiz and J. Sussex
- 000212: Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe
- J. Mestre-Ferrandiz, R. Puig-Peiro and A. Towse
- 000210: The Publicly Funded Vaccines Market in the UK
- J. Sussex and Koonal Shah
- 000206: The Publicly Funded Vaccines Market in Australia
- J. Sussex, Koonal Shah and J. Butler
- 000203: Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society
- J. Mestre-Ferrandiz, M. Garau, O'Neill, P. and J. Sussex
- 000192: The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
- A. Towse, N. Devlin, E. Hawe and L. Garrison
- 000187: Exploring the Interdependency between Public and Charitable Medical Research
- M. Garau, A. Mordoh and J. Sussex
- 000169: Time Trends in NICE HTA Decisions
- O'Neill, P., N. Devlin and R. Puig-Peiro
- 000154: The Many Faces of Innovation
- J. Mestre-Ferrandiz, A. Mordoh and J. Sussex
- 000144: International Comparisons of Medicines Prices: 2011 Indices
- O'Neill, P., R. Puig-Peiro, J. Mestre-Ferrandiz and J. Sussex
- 000050: The Expanding Value Footprint of Oncology Treatments
- J.c Rejon-Parrilla, K. Hernandez-Villafuerte, Koonal Shah, J. Mestre-Ferrandiz, L. Garrison and A. Towse
- 000001: Health and the Use of Medicines in Primary Care in Wales
- L. Baillie, E. Hawe, O'Neill, P. and R. Greville
|
|
|
|